Infinity is a public biotechnology company advancing eganelisib, a first-in-class, oral, macrophage reprogramming therapeutic candidate addressing a fundamental biologic mechanism of immune suppression in cancer.
Publicly Traded Company
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):